Loading...
You are viewing a DELETED record.
This record information is displayed for reference purpose only and should be not used.
This document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Risk Assessment generated by a regulatory process (RA)
last updated: 17 May 2022
Risk Assessment Report of the GMAC for an Approval to Release Products of TMOF yeast
EN
19 Apr 2011
-
Competent National AuthorityDepartment of Biosafety Malaysia ()Ministry of Environment and Water Level 4, Block F11, Complex F Lebuh Perdana Timur, Precinct 1Putrajaya,
62000, MalaysiaPhone: +603 80917 317,Fax: +603-8091 7371,Email: dob@biosafety.gov.my,Website: http://www.biosafety.gov.my,
-
PersonDr. Norwati AdnanDirector, Department of BiosafetyDepartment of Biosafety, Ministry of Environment and Water Ministry of Environment and Water, Level 4, Block F11, Complex F, Lebuh Perdana Timur, Precinct 1Putrajaya, Putrajaya
62000, MalaysiaPhone: +603 - 80917 319,Fax:Email: norwati@biosafety.gov.my,Website: http://www.biosafety.gov.my,
-
MOUSTICIDE™| Mr Mohd Alhafis Rusdi Changes in quality and/or metabolite content - Protein and amino acids
- GMAC RA Report_EntogeneX [ English ]
Please refer to the Risk Assessment Report
Please refer to the Risk Assessment Report
Please refer to the Risk Assessment Report
Please refer to the Risk Assessment Report
GMAC has conducted a thorough evaluation of the application for the release activities of TMOF _Yeast (Technical Grade Active Ingredient, TGAI) product and has determined that the release of this product in limited amount does not endanger biological diversity or human, animal and plant health (as per the amounts currently with the MOH). This applies to the use of Mousticide WP and Mousticide RH (produced from CEPP, UTM). However, assessment should be done again if the TMOF contains a different formulation other than the Mousticide WP and Mousticide RH as well as if these products (Mousticide WP and Mousticide RH) are produced again in another facility as there may be variables in the effectiveness of the protocols used as well as variations in the risk exposure pathways. GMAC recommends that the proposed application for release be APPROVED WITH TERMS AND CONDITIONS as listed in section IV - Proposed Terms and Conditions for Certificate of Approval. GMAC also recommends that section VI – “Identification of Issues to be addressed for subsequent release of this product” be communicated at the same time to the applicant.
Yes
Record type | Field | Record(s) | |||||
---|---|---|---|---|---|---|---|
|